Case number 1:23-cv-00775
Gilead Sciences, Inc. v. Apotex Inc. et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Jun 17, 2024 | 21 | [SEALED] Joint STATUS REPORT by Gilead Sciences, Inc.. (Tigan, Jeremy) (Entered: 06/17/2024) (0) |
| Jun 17, 2024 | 22 | REDACTED VERSION of 21 Status Report by Gilead Sciences, Inc.. (Tigan, Jeremy) (Entered: 06/17/2024) (2) |
| Jun 17, 2024 | 23 | ORAL ORDER re 21 Joint Status Report - IT IS HEREBY ORDERED that the parties' requested relief is GRANTED. ORDERED by Judge Maryellen Noreika on 6/17/2024. (dlw) (Entered: 06/17/2024) (0) |
| May 16, 2024 | 18 | [SEALED] Joint STATUS REPORT by Gilead Sciences, Inc.. (Tigan, Jeremy) (Entered: 05/16/2024) (0) |
| May 16, 2024 | 19 | REDACTED VERSION of 18 Status Report by Gilead Sciences, Inc.. (Tigan, Jeremy) (Entered: 05/16/2024) (2) |
| May 16, 2024 | 20 | ORAL ORDER re 18 Joint Status Report - IT IS HEREBY ORDERED that the parties' requested relief is GRANTED. ORDERED by Judge Maryellen Noreika on 5/16/2024. (dlw) (Entered: 05/16/2024) (0) |
| Apr 1, 2024 | N/A | SO ORDERED re 16 Stipulation and Order to Stay - IT IS HEREBY ORDERED that the stipulation and the parties' requested relief therein is GRANTED. ORDERED by Judge Maryellen Noreika on 4/1/2024. (dlw) (Entered: 04/01/2024) (0) |
| Mar 29, 2024 | 16 | [SEALED] STIPULATION and [Proposed] Order to Stay by Gilead Sciences, Inc.. (Tigan, Jeremy) (Entered: 03/29/2024) (0) |
| Mar 29, 2024 | 17 | REDACTED VERSION of 16 Stipulation by Gilead Sciences, Inc.. (Tigan, Jeremy) (Entered: 03/29/2024) (2) |
| Jan 30, 2024 | 14 | [SEALED] STIPULATION TO EXTEND TIME to submit a proposed scheduling order to April 1, 2024 - filed by Gilead Sciences, Inc.. (Tigan, Jeremy) (Entered: 01/30/2024) (0) |
| Jan 30, 2024 | 15 | REDACTED VERSION of 14 STIPULATION TO EXTEND TIME to submit a proposed scheduling order to April 1, 2024 by Gilead Sciences, Inc.. (Tigan, Jeremy) (Entered: 01/30/2024) (2) |
| Jan 30, 2024 | N/A | SO ORDERED re 14 STIPULATION TO EXTEND TIME to submit a proposed scheduling order to April 1, 2024. ORDERED by Judge Maryellen Noreika on 1/30/2024. (dlw) (Entered: 01/30/2024) (0) |
| Jan 2, 2024 | 13 | ORAL ORDER - IT IS HEREBY ORDERED that, within thirty (30) days from the date of this Order, the parties shall confer regarding proposed dates in the scheduling order and shall submit a proposed order, which is also consistent with the following guidance. A five-day bench trial will be set for 5/12/2025. The parties shall provide final contentions (i.e., final infringement and invalidity contentions, as well as final non-infringement and validity contentions) around the time that fact discovery closes (i.e., several weeks prior to or after the deadline to complete fact discovery) and at least three weeks before Plaintiff serves its opening claim construction brief. Final contentions shall include a party's contentions under its proposed construction(s), as well as under the opposing construction(s) (if such an alternative contention exists). As such, the parties are encouraged to exchange proposed claim terms and proposed constructions early in the case but in no event later than necessary to allow the parties to include alternative contentions in their final contentions. The joint claim construction chart shall be due one week after the parties have completed their exchange of final contentions, and the joint claim construction brief must be filed at least three weeks before the claim construction hearing. The parties shall leave at least three weeks between the claim construction hearing and the opening of expert discovery. The parties are to use the Court's form scheduling order, which is posted at http://www.ded.uscourts.gov (see Chambers, Judge Noreika, Forms), and the parties must include a proposal for the length and timing of trial. If there are disputes or issues that the Court needs to address in the proposed scheduling order, the parties shall direct the Court to the paragraph numbers in which those appear in a cover letter to the Court. ORDERED by Judge Maryellen Noreika on 1/2/2024. (dlw) (Entered: 01/02/2024) (0) |
| Dec 22, 2023 | 12 | ANSWER to 9 Answer to Complaint, Counterclaim by Gilead Sciences, Inc. (Tigan, Jeremy) Modified on 1/2/2024 (dlw). (Entered: 12/22/2023) (7) |
| Dec 13, 2023 | 11 | Supplemental Disclosure Statement pursuant to Rule 7.1: identifying Other Affiliate BlackRock, Inc. for Gilead Sciences, Inc. filed by Gilead Sciences, Inc.. (Tigan, Jeremy) (Entered: 12/13/2023) (3) |
| Dec 4, 2023 | 9 | ANSWER to 1 Complaint , COUNTERCLAIM against Gilead Sciences, Inc. by Apotex Inc..(Hitch, Cortlan) (Entered: 12/04/2023) (30) |
| Dec 4, 2023 | 10 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Apotex Pharmaceutical Holdings, Inc. for Apotex Inc.; Corporate Parent Aposherm Delaware Holdings Corporation for Apotex Corp. filed by Apotex Corp., Apotex Inc.. (Hitch, Cortlan) (Entered: 12/04/2023) (1) |
| Oct 4, 2023 | 7 | WAIVER OF SERVICE returned executed by Gilead Sciences, Inc.: For Apotex Corp. waiver sent on 10/3/2023, answer due 12/4/2023. (Tigan, Jeremy) (Entered: 10/04/2023) (1) |
| Oct 4, 2023 | 8 | WAIVER OF SERVICE returned executed by Gilead Sciences, Inc.: For Apotex Inc. waiver sent on 10/3/2023, answer due 12/4/2023. (Tigan, Jeremy) (Entered: 10/04/2023) (1) |
| Jul 19, 2023 | N/A | Case Assigned to Judge Maryellen Noreika. Please include the initials of the Judge (MN) after the case number on all documents filed. Associated Cases: 1:23-cv-00774-MN, 1:23-cv-00775-MN (rjb) (Entered: 07/19/2023) (0) |
| Jul 14, 2023 | 1 | Complaint* (1) |
| Jul 14, 2023 | 2 | Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (mkr) (Entered: 07/17/2023) (3) |
| Jul 14, 2023 | 3 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: June 2, 2023. Date of Expiration of Patent: U.S. Patent Nos. 8,754,065 and 9,296,769 expire on August 15, 2032. U.S. Patent Nos. 8,754,065 and 9,296,769 expire on February 15, 2033, with PED.Thirty Month Stay Deadline: 12/2/2025. (mkr) (Entered: 07/17/2023) (2) |
| Jul 14, 2023 | 4 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,754,065 B2; and 9,296,769 B2. (mkr) (Entered: 07/17/2023) (1) |
| Jul 14, 2023 | 5 | Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Gilead Sciences, Inc. (mkr) (Entered: 07/17/2023) (1) |
| Jul 14, 2023 | 6 | Summons Issued as to Apotex Corp. on 7/14/2023; and Apotex Inc. on 7/14/2023. (Attachments: # 1 Summons Issued)(mkr) (Entered: 07/17/2023) (0) |
